Susan M. O’Brien, MD of University of California Irvine, gives an overview of Abstract 233: Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia at the 58th Annual ASH Meeting in San Diego, CA.
52 Month Median PFS with Ibrutinib in Patients with Relapsed/ Refractory in CLL
